ICER is a Boston-based independent nonprofit organization that seeks to improve healthcare value by providing comprehensive clinical and cost-effectiveness analyses of treatments, tests, and procedures. The organization represents perhaps the first major US attempt to complete and publicly share comprehensive health technology assessments.
Breast cancer, the most common malignancy in women in the United States, is a serious disease associated with substantial medical and economic burden.
An Ounce of Prevention Is Not a Choice a Patient Gets to Make for Late-Stage Cancer
The new proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors can have significant budget effects, depending on the breadth of the US Food and Drug Administration (FDA)’s approved labeling. American Health & Drug Benefits asked Stephen Gorshow, MD, and James T. Kenney, RPh, MBA, to participate in a teleconference to better understand how payers are approaching the management of these agents.
Major pharmaceutical companies currently devote substantial resources to detailing activities for their major products, with estimated annual spending of $7 billion to $20 billion.
Improving Patient Outcomes and Drug Prescribing Cost-Effectiveness Through Academic Detailing
Results 1 - 6 of 6